Sweden · Delayed Price · Currency is SEK ExpreS2ion Biotech Holding AB Company Description
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally.
The company’s lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza.
It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patterns in expressed proteins.
The company has collaboration agreement with University of Oxford for the development of vaccine for malaria.
ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
| Country | Sweden |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Bent Frandsen |
Contact Details
Address: Rönnowsgatan 8c Helsingborg, 252 25 Sweden | |
| Website | expres2ionbio.com |
Stock Details
| Ticker Symbol | EXPRS2 |
| Exchange | Nasdaq Stockholm |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0008348262 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bent U. Frandsen MSc | Chief Executive Officer |
| Keith Alexander | Chief Financial Officer |
| Dr. Max M. Sogaard | Chief Scientific Officer |